Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: Evaluation against the accountability for reasonableness framework

Implementation Science

Volumn 7, Issue 1, 2012, Pages

  Mori, Amani T ^a,b   Kaale, Eliangiringa A ^a  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUORENE DERIVATIVE;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COMBINATION; DRUG INDUSTRY; ECONOMICS; HEALTH CARE PLANNING; HUMAN; INFORMATION PROCESSING; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; SAMPLE SIZE; SOCIAL BEHAVIOR; TANZANIA; TREATMENT OUTCOME;

ANTIMALARIALS; ARTEMISININS; COST-BENEFIT ANALYSIS; DATA COLLECTION; DRUG COMBINATIONS; DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE; ETHANOLAMINES; FLUORENES; HEALTH PRIORITIES; HUMANS; MALARIA, FALCIPARUM; SAMPLE SIZE; SOCIAL RESPONSIBILITY; TANZANIA; TREATMENT OUTCOME;

EID: 84858163799     PISSN: None     EISSN: 17485908     Source Type: Journal    
DOI: 10.1186/1748-5908-7-18     Document Type: Article

References (42)

1. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!. Acta Trop 2005, 95:305-315. 10.1016/j.actatropica.2005.06.009, 16098946.
2. WHO World Malaria Report, 2009 2009, Geneva, Switzerland: World Health Organization, WHO.
3. Vuorenkoski L, Toiviainen H, Hemminki E. Decision-making in priority setting for medicines--A review of empirical studies. Health Policy 2008, 86:1-9. 10.1016/j.healthpol.2007.09.007, 17950484.
4. Martin DK, Hollenberg D, MacRae S, Madden S, Singer P. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy 2003, 66:295-303. 10.1016/S0168-8510(03)00063-0, 14637013.
5. WHO Antimalarial drug combination therapy: Report of a technical consultation 2001, Geneva, Switzerland: World Health Organization, WHO.
6. National Malaria Control Programme National Guidelines for Malaria Diagnosis and Treatment 2006, Malaria control Series 11; Dar es Salaam, Tanzania, National Malaria Control Programme.
7. Canadian Agency for Drugs and Technologies in Health Guidelines for the economic evaluation of health technologies: Canada 2006, Ottawa: Canadian Agency for Drugs and Technologies in Health, 3, Canadian Agency for Drugs and Technologies in Health.
8. Ministry of Finance and Economic Affairs The Economic Survey. 2010 2009, 226. Dar es Salaam: KIUTA, Ministry of Finance and Economic Affairs.
9. Ministry of Health Second Health Sector Strategic Plan (2003-2008): Reforms towards delivering quality health services and clients satisfaction 2003, Dar es Salaam-Tanzania, Ministry of Health.
10. Ministry of Health Proposals for Health Sector Reforms 1994, Dar es Salaam-Tanzania, Ministry of Health.
11. Humba E. Pioneering Social Health Insurance in Tanzania: The case of National Health Insurance Fund (NHIF). Proceedings of Swiss TPH Spring Symposium on Improving Access Through Effective Financing 2011, Basel: UBS Training and Conference Centre.
12. Mtei GP, Mulligan J, Palmer N, Kamuzora P, Ally M, Mills A. An assessment of the health financing system in Tanzania: implications for equity and social health insurance. Report on Shield Work Package 1, Dar es Salaam, Tanzania 2007,
13. Kramera AR, Dickinson KL, Anderson RM, Fowler VG, Miranda ML, Mutero CM, Saterson KA, Wiener JB. Using decision analysis to improve malaria control policy making. Health Policy 2009, 92:133-140. 10.1016/j.healthpol.2009.02.011, 19356821.
14. Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW. The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J 2007, 6(72).
15. Mubyazi GM, Miguel A, Gonzalez B. Research influence on antimalarial drug policy change in Tanzania: case study of replacing chloroquine with sulfadoxine-pyrimethamine as the first-line drug. Malar J 2005, 4(51).
16. Holly AN, Durrheim D, Rima S. The process of changing national malaria treatment policy: lessons from country-level studies. Health Policy Plan 2003, 19(6):356-370.
17. Daniels N, Sabin J. Setting limits fairly: Can we learn to share medical resources? 2002, Oxford: Oxford University Press.
18. Daniels N, Sabin JE. Limits to health care: fair procedures, democratic deliberation and the legitimacy problem for insurers. Philos and Public Aff 1997, 26:303-350.
19. Daniels N, Sabin J. Just health: meeting health needs fairly 2008, New York: Cambridge University Press.
20. Mshana S, Shemilu H, Ndawi B, Momburi R, Olsen OE, Byskov J, Martin DK. What do District Health Planners in Tanzania think about improving priority setting using 'Accountability for Reasonableness'?. BMC Health Serv Res 2007, 7(180).
21. Maluka S, Kamuzora P, Miguel S, Byskov J, Olsen E, Shayo E, Ndawi B, Hurtig A. Decentralized health care priority-setting in Tanzania: evaluating against the accountability for reasonableness framework. SocSci Med 2010, 71:751-759.
22. Maluka S, Kamuzora P, Miguel S, Byskov J, Olsen E, Shayo E, Ndawi B, Hurtig A. Implementing accountability for reasonableness framework at district level in Tanzania: a realist evaluation. Implementation Sci 2011, 6(11).
23. Guest G, Bunce A, Johnson L. 'How many interviews are enough? An experiment with data saturation and variability. Field Methods 2006, 18:59-82.
24. Miller W, Crabtree B. Clinical research: a multimethod typology and qualitative roadmap. Doing qualitative research 1999, 20-24. London: Sage, Crabtree B, Miller W, 2.
25. Kvale S. Interviews, An Introduction to Qualitative Research Interviewing 1999, Thousand oaks: Sage publications.
26. Minzi OMS, Haule AF. Poor knowledge on new malaria treatment guidelines among drug dispensers in private pharmacies in Tanzania: the need for involving the private sector in policy preparation and implementation. East Afr J Public Health 2008, 5(2):117-121.
27. Gibson JL, Martin DK, Singer PA. Setting priorities in health care organizations: Criteria, processes and parameters of success. BMC Health Serv Res 2004, 4(25).
28. Wiseman V, Kim M, Mutabingwa TK, Whitty CJM. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Medicine 2006, 3(10).
29. Chanda P, Masiye F, Chitah B, Sipilanyambe N, Hawela M, Banda P, Okorosobo T. A cost-effectiveness analysis of artemetherlumefantrine for treatment of uncomplicated malaria in Zambia. Malar J 2007, 6(21).
30. Matowe L, Adeyi O. The quest for universal access to effective malaria treatment: how can the AMFm contribute?. Malar J 2010, 9(274).
31. Jowett M, Miller NJ. The financial burden of malaria in Tanzania: implications for future government policy. Int J Health Plann Manage 2005, 20:67-84. 10.1002/hpm.796, 15799458.
32. Hanson K, Goodman C, Lines J, Meek S, Bradley D, Mills A. The Economics of Malaria Control Interventions. Global Forum for Health Research. World Health Organization 2004,
33. Nabudere H, Upunda GL, Juma M. Policy brief on improving access to artemisinin-based combination therapies for malaria in the East African community. Int J Technol Assess Health Care 2010, 26(2):255-259. 10.1017/S026646231000019X, 20392338.
34. Lemma H, Lofgren C, San Sebastian M. Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Malar J 2011, 10(349).
35. Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, Whitty CJM. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ 2007, 334(403).
36. Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E. Over diagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ 2004, 329:1212-1218. 10.1136/bmj.38251.658229.55, 529364, 15542534.
37. Mwanziva C, Shekalaghe S, Ndaro A, Mengerink B, Megiroo S, Mosha F, Sauerwein R, Drakeley C, Gosling R, Bousema T. Overuse of artemisinin-combination therapy in MtowaMbu (river of mosquitoes), an area misinterpreted as high endemic for malaria. Malar J 2008, 7(232).
38. IHRDC IMPACT Tanzania, Interdisciplinary Monitoring Program for Antimalarial Combination Therapy in Tanzania. IHRDC., http://www. mimcom. org. uk/ifakara/impact. htm
39. Bowling A, Jacobson B, Southgate L. Exploration in consultation of the public and health professionals on priority setting in an inner London health district. SocSci Med 1993, 37(7):851-857.
40. Mullen PM. Public involvement in health care priority setting: an overview of methods for eliciting values. Health Expect 1999, 2:222-234. 10.1046/j.1369-6513.1999.00062.x, 11281899.
41. Rid A. Justice and procedure: how does "accountability for reasonableness" result in fair limit-setting decisions?. J Med Ethics 2009, 35:12-16. 10.1136/jme.2008.024430, 19103936.
42. Friedman A. Beyond accountability for reasonableness. Bioethics 2008, 22(2):101-112. 10.1111/j.1467-8519.2007.00605.x, 18251770.